Cannara Biotech Q1 Net Revenue Rises 21% to CAD 30.1 Million
I'm PortAI, I can summarize articles.
Cannara Biotech Inc. reported a 21% increase in net revenue for Q1 of fiscal 2026, totaling CAD 30.1 million. The gross profit before fair value adjustments was CAD 13.5 million, with a margin of 45%. Adjusted EBITDA reached CAD 8.8 million, while operating cash flows were CAD 8.0 million and free cash flow was CAD 3.3 million. The company's national retail market share rose to 4.1% in Q1 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments